NO20055375L - CGRP-reseptorantagonister - Google Patents

CGRP-reseptorantagonister

Info

Publication number: NO20055375L
Authority: NO; Norway
Prior art keywords: receptor antagonists; cgrp receptor; cgrp; antagonists; receptor
Prior art date: 2003-04-15

Application number

NO20055375A

Other languages

English (en)

Other versions

NO327655B1 (no

Inventor

Christopher S Burgey

Theresa M Williams

Zhengwu J Deng

Diem N Nguyen

Daniel V Paone

Anthony W Shaw

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-15

Filing date

2005-11-14

Publication date

2005-11-14

2005-11-14 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

2005-11-14 Publication of NO20055375L publication Critical patent/NO20055375L/no

2009-09-07 Publication of NO327655B1 publication Critical patent/NO327655B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Immunology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Oncology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO20055375A 2003-04-15 2005-11-14 CGRP-reseptorantagonister, farmasoytisk preparat og anvendelse av forbindelsene for fremstilling av et medikament NO327655B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US46308903P	2003-04-15	2003-04-15
US51035203P	2003-10-10	2003-10-10
PCT/US2004/011280 WO2004092168A1 (en)	2003-04-15	2004-04-09	Cgrp receptor antagonists

Publications (2)

Publication Number	Publication Date
NO20055375L true NO20055375L (no)	2005-11-14
NO327655B1 NO327655B1 (no)	2009-09-07

Family

ID=33303112

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20055375A NO327655B1 (no)	2003-04-15	2005-11-14	CGRP-reseptorantagonister, farmasoytisk preparat og anvendelse av forbindelsene for fremstilling av et medikament

Country Status (32)

Country	Link
US (6)	US6953790B2 (no)
EP (2)	EP2039694B1 (no)
JP (1)	JP3967766B2 (no)
KR (1)	KR100769030B1 (no)
CN (1)	CN100384843C (no)
AR (1)	AR045887A1 (no)
AT (1)	ATE413400T1 (no)
AU (1)	AU2004230926B2 (no)
BR (1)	BRPI0409601A (no)
CA (1)	CA2522220C (no)
CL (1)	CL2004000788A1 (no)
CO (1)	CO5640130A2 (no)
CY (1)	CY1108714T1 (no)
DE (1)	DE602004017608D1 (no)
DK (1)	DK1638969T3 (no)
EC (1)	ECSP056097A (no)
ES (1)	ES2314417T3 (no)
HR (1)	HRP20080666T3 (no)
IS (1)	IS2759B (no)
JO (1)	JO2355B1 (no)
MA (1)	MA27728A1 (no)
MX (1)	MXPA05011166A (no)
NO (1)	NO327655B1 (no)
NZ (1)	NZ543357A (no)
PE (1)	PE20050020A1 (no)
PL (1)	PL1638969T3 (no)
PT (1)	PT1638969E (no)
RU (1)	RU2308458C2 (no)
SI (1)	SI1638969T1 (no)
TW (1)	TWI314931B (no)
UA (1)	UA82877C2 (no)
WO (2)	WO2004092166A2 (no)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7220862B2 (en)	2002-06-05	2007-05-22	Bristol-Myers Squibb Company	Calcitonin gene related peptide receptor antagonists
BRPI0311812B8 (pt) *	2002-06-05	2021-05-25	Bristol Myers Squibb Co	antagonistas de receptor de peptídeo relacionado com o gene de calcitonina, composição farmacêutica e seu uso
US7842808B2 (en)	2002-06-05	2010-11-30	Bristol-Myers Squibb Company	Anti-migraine spirocycles
JP4705908B2 (ja) *	2003-04-15	2011-06-22	メルク・シャープ・エンド・ドーム・コーポレイション	Ｃｇｒｐ受容体拮抗薬
GB0310881D0 (en) *	2003-05-12	2003-06-18	Merck Sharp & Dohme	Pharmaceutical formulation
JP4705912B2 (ja) *	2003-06-26	2011-06-22	メルク・シャープ・エンド・ドーム・コーポレイション	ベンゾジアゼピンｃｇｒｐ受容体拮抗物質
CN1812982B (zh) *	2003-06-26	2010-10-27	默沙东公司	苯并二氮杂*cgrp受体拮抗剂
AR046787A1 (es)	2003-12-05	2005-12-21	Bristol Myers Squibb Co	Agentes antimigrana heterociclicos
WO2005072308A2 (en) *	2004-01-29	2005-08-11	Merck & Co., Inc.	Cgrp receptor antagonists
EP1732885A1 (en) *	2004-02-23	2006-12-20	Trustees Of Tufts College	Lactams as conformationally constrained peptidomimetic inhibitors
TW200533398A (en)	2004-03-29	2005-10-16	Bristol Myers Squibb Co	Novel therapeutic agents for the treatment of migraine
CA2582593A1 (en) *	2004-10-07	2006-04-20	Merck & Co., Inc.	Cgrp receptor antagonists
CA2583534A1 (en)	2004-10-14	2006-04-27	Merck & Co., Inc.	Cgrp receptor antagonists
JP2008517916A (ja) *	2004-10-22	2008-05-29	メルクエンドカムパニーインコーポレーテッド	Ｃｇｒｐ受容体拮抗薬
US7384930B2 (en)	2004-11-03	2008-06-10	Bristol-Myers Squibb Company	Constrained compounds as CGRP-receptor antagonists
US7384931B2 (en)	2004-11-03	2008-06-10	Bristol-Myers Squibb Company	Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en)	2004-12-03	2008-11-11	Bristol-Myers Squibb Company	Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
GB2423085C (en) *	2005-02-11	2011-11-09	Cambridge Entpr Ltd	Ligands for G-protein coupled receptors
GB2467060B (en) *	2005-02-11	2010-09-01	Cambridge Entpr Ltd	Ligands for G-protein coupled receptors
EP1861399B1 (en) *	2005-03-14	2011-12-14	Merck Sharp & Dohme Corp.	Cgrp receptor antagonists
US7834007B2 (en)	2005-08-25	2010-11-16	Bristol-Myers Squibb Company	CGRP antagonists
US8168592B2 (en)	2005-10-21	2012-05-01	Amgen Inc.	CGRP peptide antagonists and conjugates
EP1957106B2 (en)	2005-11-14	2019-07-24	Teva Pharmaceuticals International GmbH	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
CN100371327C (zh) *	2005-11-17	2008-02-27	江苏工业学院	2-氨基-6-烷氧基-3-硝基吡啶的一步合成法
US7851464B2 (en) *	2005-11-18	2010-12-14	Merck Sharp & Dohme Corp.	Spirolactam aryl CGRP receptor antagonists
US20090176986A1 (en) *	2006-04-10	2009-07-09	Mclaughlin Mark	Process for the Preparation of Pyridine Heterocycle Cgrp Antagonist Intermediate
CA2649159A1 (en)	2006-04-10	2007-10-25	Merck & Co., Inc.	Process for the preparation of cgrp antagonist
CN101421244A (zh)	2006-04-10	2009-04-29	默克公司	制备己内酰胺cgrp拮抗剂中间体的方法
WO2007120592A1 (en) *	2006-04-10	2007-10-25	Merck & Co., Inc.	Cgrp antagonist salt
EP2013213B1 (en) *	2006-05-02	2011-07-27	Bristol-Myers Squibb Company	Constrained compounds as cgrp-receptor antagonists
US7470680B2 (en)	2006-05-03	2008-12-30	Bristol-Myers Squibb Company	Constrained compounds as CGRP-receptor antagonists
BRPI0711352A2 (pt) *	2006-05-09	2011-09-27	Merck & Co Inc	composto, composição farmacêutica, e, métodos para o antagonismo de atividade receptora de cgrp em um mamìfero, e para, tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca , ou cefaléia vascular
US8163737B2 (en)	2006-06-13	2012-04-24	Vertex Pharmaceuticals Incorporated	CGRP receptor antagonists
NZ574097A (en) *	2006-06-13	2012-01-12	Vertex Pharma	Cgrp receptor antagonists
US7834000B2 (en)	2006-06-13	2010-11-16	Vertex Pharmaceuticals Incorporated	CGRP receptor antagonists
US8227603B2 (en)	2006-08-01	2012-07-24	Cytokinetics, Inc.	Modulating skeletal muscle
ES2558517T3 (es) *	2006-08-02	2016-02-04	Cytokinetics, Inc.	Ciertas entidades químicas, composiciones y métodos que comprenden imidazopirimidinas
US8299248B2 (en)	2006-08-02	2012-10-30	Cytokinetics, Incorporated	Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
AU2007293032A1 (en) *	2006-09-08	2008-03-13	Merck Sharp & Dohme Corp.	Liquid pharmaceutical formulations for oral administration of a CGRP antagonist
JP4881476B2 (ja)	2007-05-23	2012-02-22	メルク・シャープ・エンド・ドーム・コーポレイション	ピリジルピペリジン・オレキシン受容体アンタゴニスト
GB0712392D0 (en) *	2007-06-26	2007-08-01	Glaxo Group Ltd	Novel compounds
US20090075977A1 (en) *	2007-09-17	2009-03-19	Protia, Llc	Deuterium-enriched mk0974
CA2722536A1 (en)	2008-02-05	2009-08-13	Merck & Co., Inc.	Prodrugs of cgrp receptor antagonist
WO2009105348A1 (en) *	2008-02-19	2009-08-27	Merck & Co., Inc.	Imidazobenzazepine cgrp receptor antagonists
BRPI0907135B8 (pt)	2008-03-04	2021-05-25	Labrys Biologics Inc	uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica
US8143403B2 (en)	2008-04-11	2012-03-27	Bristol-Myers Squibb Company	CGRP receptor antagonists
US8044043B2 (en) *	2008-04-11	2011-10-25	Bristol-Myers Squibb Company	CGRP receptor antagonists
CA2728547A1 (en) *	2008-06-30	2010-01-07	Merck Sharp & Dohme Corp.	Solid dosage formulations of telcagepant potassium
EP2348846B1 (en) *	2008-10-21	2013-08-28	Merck Sharp & Dohme Corp.	Disubstituted azepan orexin receptor antagonists
US8715715B2 (en)	2008-11-03	2014-05-06	Nal Pharmaceuticals Ltd.	Dosage form for insertion into the mouth
CN102740884A (zh)	2009-08-28	2012-10-17	瑞纳神经科学公司	通过施用针对降钙素基因相关肽的拮抗性抗体来治疗内脏痛的方法
US8314117B2 (en) *	2009-10-14	2012-11-20	Bristol-Myers Squibb Company	CGRP receptor antagonists
US8669368B2 (en)	2010-10-12	2014-03-11	Bristol-Myers Squibb Company	Process for the preparation of cycloheptapyridine CGRP receptor antagonists
TWI487706B (zh)	2010-11-12	2015-06-11	Merck Sharp & Dohme	六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
WO2012129014A1 (en) *	2011-03-18	2012-09-27	Merck Sharp & Dohme Corp.	Piperidine carboxamide spirohydantoin cgrp receptor antagonists
US8748429B2 (en)	2011-04-12	2014-06-10	Bristol-Myers Squibb Company	CGRP receptor antagonists
PL2710039T3 (pl)	2011-05-20	2019-07-31	Alderbio Holdings Llc	Kompozycje przeciwko CGRP i ich zastosowanie
KR101965461B1 (ko)	2011-05-20	2019-04-04	앨더바이오 홀딩스 엘엘씨	필요한 대상체, 특히 편두통 환자의 광선공포증 또는 광선 혐오증을 예방 또는 억제하기 위한 항-cgrp 항체 및 항체 단편의 용도
AU2012258976B8 (en)	2011-05-20	2017-07-20	H. Lundbeck A/S	Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
WO2013010015A2 (en)	2011-07-13	2013-01-17	Cytokinetics, Inc.	Combination als therapy
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
PL2820016T3 (pl)	2012-02-27	2018-01-31	Bristol Myers Squibb Co	4 - (2 - okso-2, 3 - dihydro - 1h- imidazo [4, 5 -b]pirydyn - 1 - ylo) piperydyno - 1 - karboksylan n- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorofenylo) -6, 7, 8, 9 - tetrahydro - 5h - cyklohepta [b]pirydyn-9 - ylu, sól hemisiarczanowa
JP6062528B2 (ja)	2012-03-29	2017-01-18	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	５−アミノピリミジン誘導体及び望ましくない植物の成長を防除するためのそれらの使用
US20170114122A1 (en)	2015-10-23	2017-04-27	Alderbio Holdings Llc	Regulation of glucose metabolism using anti-cgrp antibodies
US12168004B2 (en)	2014-02-05	2024-12-17	Merck Sharp & Dohme Llc	Treatment of migraine
JP6491669B2 (ja)	2014-02-05	2019-03-27	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	Ｃｇｒｐ活性化合物の錠剤製剤
KR102274964B1 (ko)	2014-03-21	2021-07-09	테바 파마슈티컬스 인터내셔널 게엠베하	칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
US10556945B2 (en)	2014-03-21	2020-02-11	Teva Pharmaceuticals International Gmbh	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
GB201417707D0 (en)	2014-10-07	2014-11-19	Viral Ltd	Pharmaceutical compounds
WO2017001434A1 (en) *	2015-06-29	2017-01-05	Galderma Research & Development	Cgrp receptor antagonist compounds for topical treatment of skin disorders
GB201519196D0 (en)	2015-10-30	2015-12-16	Heptares Therapeutics Ltd	CGRP Receptor Antagonists
GB201519195D0 (en)	2015-10-30	2015-12-16	Heptares Therapeutics Ltd	CGRP Receptor Antagonists
GB201519194D0 (en)	2015-10-30	2015-12-16	Heptares Therapeutics Ltd	CGRP receptor antagonists
KR20190066607A (ko)	2016-09-23	2019-06-13	테바 파마슈티컬스 인터내셔널 게엠베하	불응성 편두통의 치료
EP3366286A1 (en)	2017-02-22	2018-08-29	Johannes Keller	Compounds for treating sepsis
GB201707938D0 (en)	2017-05-17	2017-06-28	Univ Sheffield	Compounds
CA3087784A1 (en)	2018-01-19	2019-07-25	Idorsia Pharmaceuticals Ltd	C5a receptor modulators
US12383545B1 (en)	2018-06-08	2025-08-12	Allergan Pharmaceuticals International Limited	Treatment of migraine
CN108892635A (zh) *	2018-09-07	2018-11-27	江苏工程职业技术学院	一种西沙必利关键中间体的制备方法
BR112020018192A2 (pt)	2019-01-08	2021-08-24	H. Lundbeck A/S	Tratamento agudo e tratamento rápido de dor de cabeça com o uso de anticorpos anti-cgrp
GB201908430D0 (en) *	2019-06-12	2019-07-24	Heptares Therapeutics Ltd	Cgrp antagonist compounds
GB201908420D0 (en)	2019-06-12	2019-07-24	Heptares Therapeutics Ltd	Cgrp antagonist compounds
AU2020202454A1 (en)	2020-04-06	2021-10-21	H. Lundbeck A/S	Treatment of most bothersome symptom (MBS) associated with migraine using anti-CGRP antibodies
CN116390712A (zh)	2020-07-29	2023-07-04	阿勒根制药国际有限公司	治疗偏头痛
WO2022140537A1 (en)	2020-12-22	2022-06-30	Allergan Pharmaceuticals International Limited	Treatment of migraine
CA3212151A1 (en)	2021-03-02	2022-09-09	Cgrp Diagnostics Gmbh	Treatment and/or reduction of occurrence of migraine
US20250109188A1 (en)	2021-08-24	2025-04-03	Cgrp Diagnostics Gmbh	Preventative treatment of migraine
CA3234080A1 (en)	2021-09-27	2023-03-30	Allergan Pharmaceuticals International Limited	Combination comprising atogepant for treating migraine
CN116903616B (zh) *	2023-07-17	2025-08-01	江西同和药业股份有限公司	一种瑞美吉泮中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4166452A (en)	1976-05-03	1979-09-04	Generales Constantine D J Jr	Apparatus for testing human responses to stimuli
US4256108A (en)	1977-04-07	1981-03-17	Alza Corporation	Microporous-semipermeable laminated osmotic system
US4265874A (en)	1980-04-25	1981-05-05	Alza Corporation	Method of delivering drug with aid of effervescent activity generated in environment of use
DE19503160A1 (de) *	1995-02-01	1996-08-08	Bayer Ag	Verwendung von Phenylcyclohexylcarbonsäureamiden
WO1996035713A1 (en)	1995-05-08	1996-11-14	Pfizer, Inc.	Dipeptides which promote release of growth hormone
ES2203246T3 (es)	1998-09-30	2004-04-01	Taisho Pharmaceutical Co., Ltd	Compuestos de isoxazoliltiofeno sustituidos.
CA2345357A1 (en) *	1998-09-30	2000-04-06	Merck Sharp & Dohme Limited	Benzimidazolinyl piperidines as cgrp ligands
BRPI0311812B8 (pt) *	2002-06-05	2021-05-25	Bristol Myers Squibb Co	antagonistas de receptor de peptídeo relacionado com o gene de calcitonina, composição farmacêutica e seu uso
JP4705908B2 (ja) *	2003-04-15	2011-06-22	メルク・シャープ・エンド・ドーム・コーポレイション	Ｃｇｒｐ受容体拮抗薬

2004
- 2004-04-07 JO JO200445A patent/JO2355B1/en active
- 2004-04-09 AT AT04749887T patent/ATE413400T1/de active
- 2004-04-09 CN CNB2004800161154A patent/CN100384843C/zh not_active Expired - Fee Related
- 2004-04-09 EP EP08105721.8A patent/EP2039694B1/en not_active Expired - Lifetime
- 2004-04-09 KR KR1020057019692A patent/KR100769030B1/ko not_active Expired - Fee Related
- 2004-04-09 DK DK04749887T patent/DK1638969T3/da active
- 2004-04-09 PL PL04749887T patent/PL1638969T3/pl unknown
- 2004-04-09 MX MXPA05011166A patent/MXPA05011166A/es active IP Right Grant
- 2004-04-09 AU AU2004230926A patent/AU2004230926B2/en not_active Ceased
- 2004-04-09 ES ES04749887T patent/ES2314417T3/es not_active Expired - Lifetime
- 2004-04-09 PT PT04749887T patent/PT1638969E/pt unknown
- 2004-04-09 DE DE602004017608T patent/DE602004017608D1/de not_active Expired - Lifetime
- 2004-04-09 NZ NZ543357A patent/NZ543357A/en not_active IP Right Cessation
- 2004-04-09 BR BRPI0409601-0A patent/BRPI0409601A/pt not_active IP Right Cessation
- 2004-04-09 WO PCT/US2004/010851 patent/WO2004092166A2/en not_active Ceased
- 2004-04-09 EP EP04749887A patent/EP1638969B1/en not_active Expired - Lifetime
- 2004-04-09 HR HR20080666T patent/HRP20080666T3/xx unknown
- 2004-04-09 JP JP2006509818A patent/JP3967766B2/ja not_active Expired - Fee Related
- 2004-04-09 SI SI200430961T patent/SI1638969T1/sl unknown
- 2004-04-09 WO PCT/US2004/011280 patent/WO2004092168A1/en not_active Ceased
- 2004-04-09 RU RU2005135440/04A patent/RU2308458C2/ru not_active IP Right Cessation
- 2004-04-09 CA CA002522220A patent/CA2522220C/en not_active Expired - Fee Related
- 2004-04-12 PE PE2004000364A patent/PE20050020A1/es not_active Application Discontinuation
- 2004-04-13 AR ARP040101238A patent/AR045887A1/es active IP Right Grant
- 2004-04-13 CL CL200400788A patent/CL2004000788A1/es unknown
- 2004-04-14 TW TW093110393A patent/TWI314931B/zh not_active IP Right Cessation
- 2004-05-04 US US10/838,835 patent/US6953790B2/en not_active Expired - Lifetime
- 2004-09-04 UA UAA200510685A patent/UA82877C2/uk unknown
2005
- 2005-06-14 US US11/152,537 patent/US7235545B2/en not_active Expired - Lifetime
- 2005-09-29 IS IS8055A patent/IS2759B/is unknown
- 2005-10-11 MA MA28550A patent/MA27728A1/fr unknown
- 2005-10-12 EC EC2005006097A patent/ECSP056097A/es unknown
- 2005-10-12 CO CO05104372A patent/CO5640130A2/es active IP Right Grant
- 2005-11-14 NO NO20055375A patent/NO327655B1/no not_active IP Right Cessation
2007
- 2007-03-14 US US11/724,066 patent/US7452903B2/en not_active Expired - Lifetime
2008
- 2008-04-09 US US12/082,233 patent/US7534784B2/en not_active Expired - Lifetime
2009
- 2009-01-15 CY CY20091100053T patent/CY1108714T1/el unknown
- 2009-04-03 US US12/417,911 patent/US7772224B2/en not_active Expired - Lifetime
2010
- 2010-07-07 US US12/831,802 patent/US7893052B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP1638969A2 (en)	2006-03-29
CN100384843C (zh)	2008-04-30
US20090192139A1 (en)	2009-07-30
US20040229861A1 (en)	2004-11-18
RU2005135440A (ru)	2006-03-20
WO2004092168A1 (en)	2004-10-28
US6953790B2 (en)	2005-10-11
CA2522220A1 (en)	2004-10-28
EP2039694A1 (en)	2009-03-25
MXPA05011166A (es)	2005-12-14
MA27728A1 (fr)	2006-01-02
ECSP056097A (es)	2006-03-01
ES2314417T3 (es)	2009-03-16
KR100769030B1 (ko)	2007-10-22
PE20050020A1 (es)	2005-02-18
HRP20080666T3 (en)	2009-01-31
CN1802376A (zh)	2006-07-12
US7235545B2 (en)	2007-06-26
AR045887A1 (es)	2005-11-16
IS8055A (is)	2005-09-29
TW200505903A (en)	2005-02-16
CO5640130A2 (es)	2006-05-31
BRPI0409601A (pt)	2006-04-18
JO2355B1 (en)	2006-12-12
IS2759B (is)	2011-10-15
ATE413400T1 (de)	2008-11-15
US20070225272A1 (en)	2007-09-27
NO327655B1 (no)	2009-09-07
US20080280857A1 (en)	2008-11-13
AU2004230926B2 (en)	2008-07-17
US20100298303A1 (en)	2010-11-25
US7772224B2 (en)	2010-08-10
CY1108714T1 (el)	2014-04-09
DK1638969T3 (da)	2009-01-26
EP1638969B1 (en)	2008-11-05
AU2004230926A1 (en)	2004-10-28
TWI314931B (en)	2009-09-21
JP2006523697A (ja)	2006-10-19
CL2004000788A1 (es)	2005-02-25
KR20050121734A (ko)	2005-12-27
WO2004092166A2 (en)	2004-10-28
US7893052B2 (en)	2011-02-22
UA82877C2 (en)	2008-05-26
HK1090922A1 (en)	2007-01-05
US7452903B2 (en)	2008-11-18
RU2308458C2 (ru)	2007-10-20
CA2522220C (en)	2009-06-23
DE602004017608D1 (de)	2008-12-18
PL1638969T3 (pl)	2009-04-30
EP2039694B1 (en)	2014-03-26
SI1638969T1 (sl)	2009-02-28
NZ543357A (en)	2008-08-29
WO2004092166A3 (en)	2005-01-20
PT1638969E (pt)	2009-01-16
JP3967766B2 (ja)	2007-08-29
US20050256098A1 (en)	2005-11-17
US7534784B2 (en)	2009-05-19

Publication	Publication Date	Title
ATE413400T1 (de)	2008-11-15	Cgrp-rezeptorantagonisten
DK1682142T3 (da)	2012-10-15	M3-muscarin-acetylcholin-receptor-antagonister
DK1951660T3 (da)	2014-01-27	Histamin-3-receptorantagonister
ATE494285T1 (de)	2011-01-15	Muscarinische acetylcholin-rezeptor-antagonisten
NO20051871D0 (no)	2005-04-18	Opioid reseptorantagonister
CY2015029I2 (el)	2016-04-13	Τρικυκλικοι ανταγωνιστες υποδοχεα θρομβινης
DK1720859T3 (da)	2010-04-26	Chemokinreceptorantagonister
PT2570128T (pt)	2016-10-07	Antagonistas do receptor muscarínico de acetilcolina
EP1641781A4 (en)	2010-06-23	BENZODIAZEPINE-CGRP Receptor Antagonists
EP1765805A4 (en)	2009-08-26	CGRP RECEPTOR ANTAGONISTS
DK1711465T3 (da)	2008-03-31	Hydroisoindolin-tachykinikreceptorantagonister
DE60216229D1 (de)	2007-01-04	Il-8-rezeptorantagonisten
DK1973886T3 (da)	2013-03-18	Prokineticin-1-receptor-antagonister
DE60316411D1 (de)	2007-10-31	Thiazolderivate als npy-rezeptorantagonisten
EP1799672A4 (en)	2011-01-19	CGRP RECEPTOR ANTAGONIST
FI20060188L (fi)	2006-02-24	Modifioidut IL-4-muteiinin reseptorin antagonistit
EE200300335A (et)	2003-12-15	Histamiiniretseptori antagonistid
ATE528291T1 (de)	2011-10-15	Cyclopropylderivate als nk3 rezeptor-antagonisten
ATE320254T1 (de)	2006-04-15	Crf receptor antagonisten
EP1534736A4 (en)	2006-11-02	ANTAGONISTS OF NOGO RECEPTOR
DE602004018527D1 (de)	2009-01-29	Furanderivate als ep4-rezeptorantagonisten
DE602005007719D1 (de)	2008-08-07	Antagonisten des opioidrezeptors

Legal Events

Date	Code	Title	Description
2015-11-23	MM1K	Lapsed by not paying the annual fees